Model for measuring the impact of good pharmacovigilance practices of COVID-19 patients on hcp reactivity: Morocco case study

Abstract

This paper presents a conceptual model used to evaluate how the improvement of good pharmacovigilance practices by patients during COVID-19 period influences the reactivity of the healthcare professionals (HCPs) in the Draa Tafilalet region in Morocco, concerning the reporting of adverse drug reactions (ADRs) through barriers that influence the reporting from both patients and HCPs. The empirical study is based on a survey submitted to a sample of a total of 180 HCP and on the application of latent variable structural modelling through the partial least squares (PLS) method. The 2017 version of the XL-STAT software served to perform the statistical calculations. The study investigates the reliability and validity of the proposed model. Our conclusions show that the improvement of good pharmacovigilance practices impact positively the reactivity of HCP in terms of ADRs reporting. The reliability of the measurement was > 0.7, which allowed us to test the internal and external validity of our conceptual model. 11 hypotheses were validated against two invalid derivative hypotheses. Spontaneous ADRs reporting is the cornerstone of any pharmacovigilance system aiming to maintain patient safety. Our findings indicate the necessity firstly, to initiate a training program on reporting for all HCPs, and secondly, to inform the general public about the national pharmacovigilance center, where ADRs can be reported. Both initiatives aim to keep the culture of ADR reporting perennial.